---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-010487"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-05-11T21:17:22+00:00"
generated_at: "2026-05-11T21:19:15.814309+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tonix Q1 net loss $40.2M; TONMYA launch generates $3.7M revenue with 2,145 prescribers

## Summary
- Net product revenue $6.9M (TONMYA $3.7M, legacy products $3.2M); net loss $40.2M ($2.93/share).
- Cash $185.5M at Mar 31; raised $22.6M post-quarter via ATM; runway into early Q2 2027.
- TONMYA Q1: 2,145 HCPs prescribed, 3,588 patients initiated, ~5,400 Rx; cumulative 11,016 Rx through May 1.
- Secured GPO agreement covering ~35M commercial lives; Medicaid coverage in 38 states (~55M lives).
- TNX-4800 Phase 2 Lyme prevention study planned for 2027; TNX-102 SL MDD Phase 2 to start mid-2026.

## SEC filing metadata
- accession: 0001999371-26-010487
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-05-11T21:17:22+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/0001999371-26-010487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/tnxp-8k_051126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-010487
- JSON: https://secwatch.observer/filing/0001999371-26-010487.json
- Plain text: https://secwatch.observer/filing/0001999371-26-010487.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 11, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2026. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/0001999371-26-010487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.